Patrick Trucchio
Stock Analyst at HC Wainwright & Co.
(3.19)
# 1,151
Out of 4,667 analysts
302
Total ratings
33.57%
Success rate
5.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Patrick Trucchio
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $60 | $18.71 | +220.68% | 18 | Nov 20, 2024 | |
| VIR Vir Biotechnology | Reiterates: Buy | $110 | $6.74 | +1,532.05% | 20 | Nov 20, 2024 | |
| IVVD Invivyd | Maintains: Buy | $15 → $10 | $0.77 | +1,201.91% | 14 | Nov 20, 2024 | |
| GHRS GH Research | Reiterates: Buy | $40 | $10.95 | +265.30% | 11 | Nov 20, 2024 | |
| SLN Silence Therapeutics | Reiterates: Buy | $75 | $6.93 | +982.25% | 19 | Nov 20, 2024 | |
| CYBN Cybin | Reiterates: Buy | $190 | $11.16 | +1,602.51% | 15 | Nov 19, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Buy | $400 | $248.79 | +60.78% | 22 | Nov 18, 2024 | |
| ATAI Atai Life Sciences | Maintains: Buy | $15 → $10 | $1.59 | +528.93% | 14 | Nov 18, 2024 | |
| SGMO Sangamo Therapeutics | Reiterates: Buy | $10 | $1.95 | +412.82% | 19 | Nov 14, 2024 | |
| ONCY Oncolytics Biotech | Reiterates: Buy | $5 | $1.00 | +400.75% | 15 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $8.05 | +49.07% | 12 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $5.36 | +459.70% | 6 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $0.70 | +1,335.75% | 14 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $55 | $7.52 | +631.38% | 16 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $24.49 | +226.66% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $5.70 | +338.60% | 10 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $60 | $4.66 | +1,187.55% | 12 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $100 | $32.42 | +208.45% | 16 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $60 | $59.77 | +0.38% | 14 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $1.86 | +1,244.09% | 14 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $7.18 | +735.65% | 13 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $170 → $68 | $10.66 | +537.90% | 2 | Sep 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $230 → $20 | $0.94 | +2,029.47% | 2 | Dec 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $340 | $260.15 | +30.69% | 1 | Aug 18, 2021 |
Arrowhead Pharmaceuticals
Nov 20, 2024
Reiterates: Buy
Price Target: $60
Current: $18.71
Upside: +220.68%
Vir Biotechnology
Nov 20, 2024
Reiterates: Buy
Price Target: $110
Current: $6.74
Upside: +1,532.05%
Invivyd
Nov 20, 2024
Maintains: Buy
Price Target: $15 → $10
Current: $0.77
Upside: +1,201.91%
GH Research
Nov 20, 2024
Reiterates: Buy
Price Target: $40
Current: $10.95
Upside: +265.30%
Silence Therapeutics
Nov 20, 2024
Reiterates: Buy
Price Target: $75
Current: $6.93
Upside: +982.25%
Cybin
Nov 19, 2024
Reiterates: Buy
Price Target: $190
Current: $11.16
Upside: +1,602.51%
Alnylam Pharmaceuticals
Nov 18, 2024
Reiterates: Buy
Price Target: $400
Current: $248.79
Upside: +60.78%
Atai Life Sciences
Nov 18, 2024
Maintains: Buy
Price Target: $15 → $10
Current: $1.59
Upside: +528.93%
Sangamo Therapeutics
Nov 14, 2024
Reiterates: Buy
Price Target: $10
Current: $1.95
Upside: +412.82%
Oncolytics Biotech
Nov 14, 2024
Reiterates: Buy
Price Target: $5
Current: $1.00
Upside: +400.75%
Nov 14, 2024
Reiterates: Buy
Price Target: $12
Current: $8.05
Upside: +49.07%
Nov 14, 2024
Reiterates: Buy
Price Target: $30
Current: $5.36
Upside: +459.70%
Nov 11, 2024
Reiterates: Buy
Price Target: $10
Current: $0.70
Upside: +1,335.75%
Nov 11, 2024
Reiterates: Buy
Price Target: $55
Current: $7.52
Upside: +631.38%
Nov 7, 2024
Reiterates: Buy
Price Target: $80
Current: $24.49
Upside: +226.66%
Nov 6, 2024
Reiterates: Buy
Price Target: $25
Current: $5.70
Upside: +338.60%
Nov 1, 2024
Maintains: Buy
Price Target: $120 → $60
Current: $4.66
Upside: +1,187.55%
Oct 24, 2024
Reiterates: Buy
Price Target: $100
Current: $32.42
Upside: +208.45%
Oct 15, 2024
Downgrades: Neutral
Price Target: $80 → $60
Current: $59.77
Upside: +0.38%
Oct 14, 2024
Reiterates: Buy
Price Target: $25
Current: $1.86
Upside: +1,244.09%
Aug 22, 2024
Reiterates: Buy
Price Target: $60
Current: $7.18
Upside: +735.65%
Sep 23, 2022
Maintains: Buy
Price Target: $170 → $68
Current: $10.66
Upside: +537.90%
Dec 28, 2021
Maintains: Buy
Price Target: $230 → $20
Current: $0.94
Upside: +2,029.47%
Aug 18, 2021
Maintains: Outperform
Price Target: $260 → $340
Current: $260.15
Upside: +30.69%